Company Filing History:
7 out of 431 
6 out of 272 
1 out of 45 
Years Active: 2013-2020
Title: Koichi Akashi: Innovator in Antibody Therapeutics
Introduction
Koichi Akashi is a prominent inventor based in Fukuoka, Japan. He has made significant contributions to the field of antibody therapeutics, particularly in the treatment of blood tumors. With a total of 7 patents to his name, Akashi's work has the potential to impact the lives of many patients suffering from various hematological malignancies.
Latest Patents
Among his latest patents is the development of an anti-TIM-3 antibody. This invention involves a monoclonal antibody or its fragment that binds to the extracellular region of TIM-3, exhibiting high antibody-dependent cellular cytotoxicity (ADCC) activity. The patent also covers a hybridoma that produces this antibody, along with the DNA encoding it, a vector for introducing the DNA, and a method for producing the antibody using the hybridoma or transformant. Additionally, Akashi has disclosed a therapeutic method for treating blood tumors by administering the TIM-3 antibody to patients with specific cell fractions expressing TIM-3. This method targets various blood tumor cells, including AML, CML, MDS, ALL, CLL, and multiple myeloma cells.
Career Highlights
Koichi Akashi has worked with notable institutions such as Kyushu University and Kyowa Hakko Kirin Co., Limited. His research and innovations have positioned him as a key figure in the development of novel therapeutic agents for blood-related diseases.
Collaborations
Some of his notable coworkers include Yoshimasa Inagaki and Yoshikane Kikushige. Their collaborative efforts have contributed to advancing research in antibody therapeutics.
Conclusion
Koichi Akashi's innovative work in the field of antibody therapeutics showcases his dedication to improving treatment options for patients with blood tumors. His patents and collaborations reflect a commitment to advancing medical science and enhancing patient care.